Revvity's AI Trade Grew Up — and Management Just Showed You the Bill for Q4
A 47% ninety-day run, AI demand leaking out of high-content screening into reagents and detection, and a fourth-quarter guide that quietly hands back the upside it just booked.
RVTY · Earnings Call · 2026-11-03
From the microscope to the wet lab
For four quarters Revvity's AI story was a single instrument family. High-content screening, Opera Phenix, OptIQ, lab-in-the-loop data generation — one product line carrying an entire narrative while the rest of the portfolio dragged. That changed in Q3 2026, and it is the reason the stock has run +47% in 90 trading days against a tape that has been merciless to AI hardware.
“AI related demand is beginning to be seen across a wider cross section of our offerings but it is still in its very early days.” — Prahlad R. Singh, President and Chief Executive Officer · 2026-11-03
The evidence is in the mix, not the headline. Total revenue of $710 million with 7% pro forma organic growth against a mid-single-digit guide; life sciences at $380 million up 9% organic; diagnostics at $330 million up 5%. But the standout was life science reagents growing high single digits — the strongest print in several years — with instruments up strong mid single digits and Signals software up in the upper teens. The high content screening franchise kept accelerating despite tough comps, and management says backlog grew across almost every instrument group in the portfolio.
Prahlad Singh was careful to split the credit: “the fundamental recovery that we are seeing in the pharma biotech market is obviously helping the full instruments portfolio. So, obviously, AI is a catalyst, but overall, there is a strong fundamental recovery in the base market.” — Prahlad R. Singh, President and Chief Executive Officer · 2026-11-03 That distinction matters. A year ago this was a niche capital-equipment order story; now it is a cyclical recovery plus an AI kicker. The incremental AI demand is spreading from screening into high-throughput detection, with imaging and in vivo positioned for 2027.
The give-back nobody wants to underwrite
The awkward part of an otherwise excellent quarter is that the fourth quarter is guided down to roughly 5% organic from 7%. Two things explain it, and only one is timing. First, the bulk order that flattered reagents in Q3 — Maxwell Krakowiak put it at “maybe a 100-basis-point contribution to the reagents business within the quarter” — Maxwell Krakowiak, Senior Vice President and Chief Financial Officer · 2026-11-03 — pulled forward from Q4. Second, software moderates from high teens to mid teens. Analysts hammered this seam for three separate questions, and the answer was consistently "no flush, just timing":
There was no backlog flush within the period. Our backlog continued to grow and accelerate as we exited the third quarter. And again, that was broad based improvement.
What management did raise is the instrument outlook for Q4 to high single digits, and the numbers underneath the headline are the real story. Pro forma adjusted operating margin of 29.4%, roughly 40 basis points ahead, on incrementals north of 40% — Krakowiak called the low-40s incremental framework “sustainable” — Maxwell Krakowiak, Senior Vice President and Chief Financial Officer · 2026-11-03, and this is the third consecutive quarter the full-year margin outlook has gone up, now 28.8%. Diagnostics margins ex-China expanded more than 600 basis points year over year.
Here is where the fundamentals axis keeps you honest. The GAAP operating margin sat at just 12.2% in the June quarter on $730 million of revenue, a series that has gone essentially nowhere since 2019. A company whose revenue line has been flat for six years telling you it just discovered its "true potential" deserves a raised eyebrow — but the margin line is where the operating leverage actually shows, and it is accelerating.
What stopped being said
The most telling signal in this call is absence. For three straight quarters — 2026Q1 through Q3 — the immunodiagnostics business in China was the single loudest thread on the call, a 20%-plus-declining, DRG-policy-hammered segment that management shrank, hedged, and eventually agreed to divest. This quarter it is a footnote: 160 basis points of margin headwind, flagged once, then dropped. The reason is that the story is now told on a pro forma basis, ex-China, with the deal expected to close next year.
Same with the tariff refund — the number-one keyword in the June-quarter transcript, worth real dollars and half of an EPS raise — which has vanished entirely. Two of the loudest crutches from the last twelve months are simply gone, replaced by a growth story that no longer needs them. That is a genuinely bullish tell.
But there's a subtle tension in the AI narrative. Revvity's own keyword history shows AI-adjacent themes — data generation, massive data sets, validation, lab-in-the-loop — climbing since mid-2025, and on the June call management was emphatic that it was too early to size: “it's so early, and it is — the growth spurt is just at the very beginning so that it's very — going to be very tough even for us to put our arms around it.” — Prahlad Singh, President and Chief Executive Officer · 2026-08-04 Now the language has shifted from "we cannot size it" to "it is broadening into 2027." That is progress — but it is a narrative upgrade, not a quantification. Nobody on this call put a percentage of revenue on AI exposure, and Singh explicitly declined to do so.
The divergence trade
The tape is the most interesting part. Revvity is up 47% in 90 days, a genuine name-in-motion move, while the global AI-hardware complex that everyone assumes is the trade has been dismantled: high-bandwidth memory, co-packaged optics, HBM-adjacent semis, and bitcoin-miner-turned-datacenter names are down 25-40% over the same window in the global price tape. Meanwhile the themes that are working read like a life-sciences rotation — Life Science tools among the 90-day advancers, Pulsed Field Ablation up 38%, early-stage cancer names up 88%.
Revvity sits at the intersection: a beaten-down tools franchise, still 18.7% below its 2021 peak, that suddenly has an AI narrative attached to wet-lab reagents and instruments rather than to GPUs. That is a much cheaper way to own the idea — 4.3x price to revenue — and it explains why a 5% organic growth company with a Q4 step-down can still rip.
The balance sheet supports patience: $2.2 billion of net debt, 2.3x net leverage heading to roughly 2.0x by year-end, 100% fixed-rate debt at a 2.8% weighted average and a seven-year average maturity — a genuinely advantaged liability stack in a high-rate world. Free cash flow of $152 million in the quarter at 99% conversion, and over $450 million year to date at 105%, is not a growth-company luxury; it is the funding for the tuck-in M&A and buyback optionality Singh keeps flagging.
The verdict
This was the quarter where incremental margin rhetoric and fundamental recovery rhetoric finally converged in the actual print — 21% EPS growth, third margin raise of the year, guidance lifted to $5.40-5.45 and roughly $2.86 billion in pro forma revenue. The skeptics' case is contained entirely in the Q4 bridge: pull out the bulk orders and software moderation, and the underlying number is closer to mid-single. The bulls' case is that drug discovery budgets have turned, backlog is building across every instrument platform, and the AI demand that started in one product family is now leaking into reagents and detection with 2027 in front of it.
Next week's Investor Day — where Singh has promised to explain how science and R&D are changing because of AI — is the moment to convert narrative into a number. Until then, the tape has already made its bet.